Vetter to Begin GMP Filling Following Full Validation

By Dan Stanton

- Last updated on GMT

Vetter to Begin GMP Filling Following Full Validation
Vetter says demand for prefilled-syringes will be accommodated by its newly approved commercial filling line.

The new commercial filling line at Vetter’s Ravensburg, Germany facility has received full validation and is prepped to begin current good manufacturing practice (cGMP) filling, following the successful media-fill completion.

A Managing Director of the contract development and manufacturing organization (CDMO), Peter Soelkner, said in a press statement “Vetter continues to expand its prefilled-syringe capabilities due to increased customer demand.”

He continued, adding Vetter was now able to accommodate the needs of customers, whether “small-batch clinical fills or high-volume commercial fills,”​ in its line which is currently capable of filling 1ml  standard-format syringes.

Amongst the offerings of Vetter’s new systems are a number of techniques to maximize API yield. These include: Shortening distances between the compounding and filling areas, fully automating syringe closures (using a 3D scanner prior to filling) to minimize API loss and reduce contamination risk, and using an automatic weighing system to ensure exact filling quantities.

Vetter has said it already has one customer project underway, with a number of others to follow. The company would not divulge who the client was.

In 2011, Vetter inked a deal with West​ Pharmaceuticals in which West’s Crystal Zenith non-glass device​ – produced in conjunction with Daikyo Seiko, Japanese manufacturers - would be filled at the Ravensburg site. The joint venture was in response to safety issues with pre-filled syringes on the market at the time and on-going stress on cGMPs and pharmaceutical practices.

FDA Inspection

This boost for Vetter comes just a fortnight after the company’s newest facility – an 18,000m2 warehouse for both cold-storage and room temperature products – received its first approval of GMP by the US Food and Drug Administration (FDA), following an inspection in mid-March.

The facility which opened last May​ also at the Ravensburg location was described at the time by Managing Director, Thomas Otto, as a fundamental part of Vetter’s worldwide system. The site has already been granted European cGMP accreditation and approved for manufacturing.

Related news

Show more

Related products

show more

Import Risks & Clinical Supply Depots

Import Risks & Clinical Supply Depots

Catalent Pharma Solutions | 07-Nov-2018 | Case Study

A sponsor running a clinical trial in Israel arranged to ship their clinical trial product from Europe to a depot in Israel. With the protocol based in...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Discover Fermion’s new API unit 4 in Hanko

Discover Fermion’s new API unit 4 in Hanko

Recorded the 04-Sep-2018 | Webinar

Join this webinar to learn more about Fermion’s new manufacturing unit 4 at the Hanko site. This webinar will provide virtual tour to our new state of...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars